Merck KGaA said its Ezmekly therapy for people with a rare genetic disorder has received the conditional marketing approval ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) ...

Review the current Merck & Co Inc (MRK:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MRK is the best investment for you.